Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime?

× No keyword cloud information.

14 in total

1. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.

Authors: Manish A Shah; Minaxi Jhawer; David H Ilson; Robert A Lefkowitz; Edric Robinson; Marinela Capanu; David P Kelsen
Journal: J Clin Oncol Date: 2010-12-28 Impact factor: 44.544

2. A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction.

Authors: Juan W Valle; Anne Armstrong; Chris Newman; Valery Alakhov; Grzegorz Pietrzynski; Julie Brewer; Sue Campbell; Pippa Corrie; Eric K Rowinsky; Malcolm Ranson
Journal: Invest New Drugs Date: 2010-02-24 Impact factor: 3.850

Review 3. Locally advanced and metastatic gastric cancer: current management and new treatment developments.

Authors: Kathryn Field; Michael Michael; Trevor Leong
Journal: Drugs Date: 2008 Impact factor: 9.546

4. High pathologic complete remission rate from induction docetaxel, platinum and fluorouracil (DCF) combination chemotherapy for locally advanced esophageal and junctional cancer.

Authors: Vanita Noronha; Amit Joshi; Sunny Jandyal; Nirmala Jambhekar; Kumar Prabhash
Journal: Med Oncol Date: 2014-08-23 Impact factor: 3.064

Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime?

1. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.

2. A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction.

Review 3. Locally advanced and metastatic gastric cancer: current management and new treatment developments.

4. High pathologic complete remission rate from induction docetaxel, platinum and fluorouracil (DCF) combination chemotherapy for locally advanced esophageal and junctional cancer.

Review 5. Methylation-mediated gene silencing as biomarkers of gastric cancer: a review.

Review 6. Chemotherapy for advanced gastric cancer.

7. Advanced gastric cancer: an update and future directions.

Review 8. Advances in the pharmacological treatment of gastro-oesophageal cancer.

9. HDM2 regulation by AURKA promotes cell survival in gastric cancer.

10. The BC Cancer Agency Compassionate Access Program: outcome analysis of patients with esophagogastric cancer.